Navigation Links
Initiation of Coverage Informational Review Issued by Scimitar Equity Research
Date:12/17/2007

BOSTON, Dec. 17 /PRNewswire/ -- Scimitar Equity Research, Inc. issues a review on Nventa Biopharmaceuticals Corporation (TSX: NVN) entitled: "A Very Promising Therapeutic and Vaccine Candidate for the Treatment of Diseases Caused by the Human Papillomavirus (HPV)." The analyst research is available on Scimitar's website: http://www.scimitarequity.com.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

About HspE7, Nventa's Lead Product Candidate:

HspE7 is a novel therapeutic vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Heat shock proteins (Hsps), also known as stress proteins, are naturally present in the human body and play important roles in the immune system, including transporting substances within cells and activating cells of the immune system.

Scimitar Equity Research, Inc. provides equity research of emerging healthcare companies for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about NVN.TO (TSX) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any inve
'/>"/>

SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Latanoprost Market, ... Developed by Pharmacia & Upjohn in 1995, latanoprost ... reduces intraocular pressure. As the first pressure- lowering ... name of Xalatan) entered China ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions ... it should begin with the employer and employees getting together for meaningful group ...
(Date:8/28/2015)... ... ... Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and associated ... pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor of ... earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic and ...
(Date:8/28/2015)... ... ... Mendon, IL, home of the Adams County Fairgrounds, was treated once again to ... In its second year, the “Music With A Mission” benefit concert was held there ... “Music With A Mission” is to raise money to help fund music education programs ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ... is now selling External Counterpulsation (EECP or ECP) machines with a full clinic licence ... been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... associated with age, might affect women with diabetes or ... recent study .// ,The study shows elderly ... and are at an increased risk for developing cognitive ... women with pre-diabetes or diabetes was increased nearly two-fold. ...
... say that they have now found out that long-term use ... of cancer.// ,The trial results of the longest follow-up ... show cardiovascular death was reduced by 17 percent and coronary ... drug simvastatin, also known as Zocor, for 10 years compared ...
... 600 babies in the United States is born with an isolated ... cleft only // and no other birth defects. ,Researchers say ... if a couple will have a child born with a cleft ... According to researchers isolated clefts happen during early fetal development. ...
... a degenerative joint disease and one of the oldest ... the joint’s cartilage breaks down and the bones rub ... ,An international, multi-center study shows an effective treatment ... as Prexige. The drug was found to reduces gastric ...
... public places can improve the overall likelihood someone will ... AEDs -- devices capable of shocking the heart back ... 1,000 shopping malls, apartment complexes, and other public places ... volunteers in these communities were then trained in either ...
... recent study researchers say cancer patients who receive treatment have ... new study shows many doctors are not taking the necessary ... more than 100 oncologists to determine if the doctors were ... preventative measures used by the physicians. About 40 percent of ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: